Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Association Between 3 Doses of mRNA COVID-19 Vaccine and Symptomatic Infection Caused by the SARS-CoV-2 Omicron and Delta Variants
Emma K. Accorsi, Amadea Britton, Katherine E. Fleming-Dutra, et al.
JAMA (2022) Vol. 327, Iss. 7, pp. 639-639
Open Access | Times Cited: 643

Showing 1-25 of 643 citing articles:

SARS-CoV-2 variant biology: immune escape, transmission and fitness
Alessandro M. Carabelli, Thomas P. Peacock, Lucy Thorne, et al.
Nature Reviews Microbiology (2023)
Open Access | Times Cited: 937
Effectiveness of mRNA-1273 against SARS-CoV-2 Omicron and Delta variants
Hung Fu Tseng, Bradley K. Ackerson, Yi Luo, et al.
Nature Medicine (2022) Vol. 28, Iss. 5, pp. 1063-1071
Open Access | Times Cited: 491
SARS-CoV-2 Omicron variant: recent progress and future perspectives
Yao Fan, Xiang Li, Lei Zhang, et al.
Signal Transduction and Targeted Therapy (2022) Vol. 7, Iss. 1
Open Access | Times Cited: 471
Waning 2-Dose and 3-Dose Effectiveness of mRNA Vaccines Against COVID-19–Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Adults During Periods of Delta and Omicron Variant Predominance — VISION Network, 10 States, August 2021–January 2022
Jill M. Ferdinands, Suchitra Rao, Brian E. Dixon, et al.
MMWR Morbidity and Mortality Weekly Report (2022) Vol. 71, Iss. 7, pp. 255-263
Open Access | Times Cited: 423
Evolution of the SARS‐CoV‐2 omicron variants BA.1 to BA.5: Implications for immune escape and transmission
Lok Bahadur Shrestha, Charles S. P. Foster, William D. Rawlinson, et al.
Reviews in Medical Virology (2022) Vol. 32, Iss. 5
Open Access | Times Cited: 406
COVID-19 Incidence and Death Rates Among Unvaccinated and Fully Vaccinated Adults with and Without Booster Doses During Periods of Delta and Omicron Variant Emergence — 25 U.S. Jurisdictions, April 4–December 25, 2021
Amelia G. Johnson, Avnika B. Amin, Akilah R. Ali, et al.
MMWR Morbidity and Mortality Weekly Report (2022) Vol. 71, Iss. 4, pp. 132-138
Open Access | Times Cited: 311
Current evidence on efficacy of COVID‐19 booster dose vaccination against the Omicron variant: A systematic review
Santenna Chenchula, Padmavathi Karunakaran, Sushil Sharma, et al.
Journal of Medical Virology (2022) Vol. 94, Iss. 7, pp. 2969-2976
Open Access | Times Cited: 294
A CRISPR/Cas12a-empowered surface plasmon resonance platform for rapid and specific diagnosis of the Omicron variant of SARS-CoV-2
Zhi Chen, Jingfeng Li, Tianzhong Li, et al.
National Science Review (2022) Vol. 9, Iss. 8
Open Access | Times Cited: 283
Estimated Effectiveness of COVID-19 Vaccines Against Omicron or Delta Symptomatic Infection and Severe Outcomes
Sarah A. Buchan, Hannah Chung, Kevin A. Brown, et al.
JAMA Network Open (2022) Vol. 5, Iss. 9, pp. e2232760-e2232760
Open Access | Times Cited: 277
mRNA-1273 or mRNA-Omicron boost in vaccinated macaques elicits similar B cell expansion, neutralizing responses, and protection from Omicron
Matthew Gagné, Juan I. Moliva, Kathryn E. Foulds, et al.
Cell (2022) Vol. 185, Iss. 9, pp. 1556-1571.e18
Open Access | Times Cited: 210
Imprinted antibody responses against SARS-CoV-2 Omicron sublineages
Young‐Jun Park, Dora Pinto, Alexandra C. Walls, et al.
Science (2022) Vol. 378, Iss. 6620, pp. 619-627
Open Access | Times Cited: 193
Infectiousness of SARS-CoV-2 breakthrough infections and reinfections during the Omicron wave
Sophia T. Tan, Ada Kwan, Isabel Rodríguez-Barraquer, et al.
Nature Medicine (2023) Vol. 29, Iss. 2, pp. 358-365
Open Access | Times Cited: 184
Omicron spike function and neutralizing activity elicited by a comprehensive panel of vaccines
John E. Bowen, Amin Addetia, Ha V. Dang, et al.
Science (2022) Vol. 377, Iss. 6608, pp. 890-894
Open Access | Times Cited: 174
Effectiveness of COVID-19 Pfizer-BioNTech BNT162b2 mRNA Vaccination in Preventing COVID-19–Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Nonimmunocompromised Children and Adolescents Aged 5–17 Years — VISION Network, 10 States, April 2021–January 2022
Nicola P. Klein, Melissa S. Stockwell, Maria Demarco, et al.
MMWR Morbidity and Mortality Weekly Report (2022) Vol. 71, Iss. 9, pp. 352-358
Open Access | Times Cited: 170
COVID-19 vaccine update: vaccine effectiveness, SARS-CoV-2 variants, boosters, adverse effects, and immune correlates of protection
Wei-Yu Chi, Yen-Der Li, Hsin‐Che Huang, et al.
Journal of Biomedical Science (2022) Vol. 29, Iss. 1
Open Access | Times Cited: 166
Myopericarditis following COVID-19 vaccination and non-COVID-19 vaccination: a systematic review and meta-analysis
Ryan Ruiyang Ling, Kollengode Ramanathan, Felicia Liying Tan, et al.
The Lancet Respiratory Medicine (2022) Vol. 10, Iss. 7, pp. 679-688
Open Access | Times Cited: 139
Association of Prior BNT162b2 COVID-19 Vaccination With Symptomatic SARS-CoV-2 Infection in Children and Adolescents During Omicron Predominance
Katherine E. Fleming-Dutra, Amadea Britton, Nong Shang, et al.
JAMA (2022) Vol. 327, Iss. 22, pp. 2210-2210
Open Access | Times Cited: 139
Durability of BNT162b2 vaccine against hospital and emergency department admissions due to the omicron and delta variants in a large health system in the USA: a test-negative case–control study
Sara Y. Tartof, Jeff Slezak, Laura Puzniak, et al.
The Lancet Respiratory Medicine (2022) Vol. 10, Iss. 7, pp. 689-699
Open Access | Times Cited: 133
Early Estimates of Bivalent mRNA Booster Dose Vaccine Effectiveness in Preventing Symptomatic SARS-CoV-2 Infection Attributable to Omicron BA.5– and XBB/XBB.1.5–Related Sublineages Among Immunocompetent Adults — Increasing Community Access to Testing Program, United States, December 2022–January 2023
Ruth Link‐Gelles, Allison Avrich Ciesla, Lauren E. Roper, et al.
MMWR Morbidity and Mortality Weekly Report (2023) Vol. 72, Iss. 5, pp. 119-124
Open Access | Times Cited: 130
Vaccine effectiveness against SARS-CoV-2 infection or COVID-19 hospitalization with the Alpha, Delta, or Omicron SARS-CoV-2 variant: A nationwide Danish cohort study
Mie Agermose Gram, Hanne‐Dorthe Emborg, Astrid Blicher Schelde, et al.
PLoS Medicine (2022) Vol. 19, Iss. 9, pp. e1003992-e1003992
Open Access | Times Cited: 127
Effectiveness of heterologous and homologous covid-19 vaccine regimens: living systematic review with network meta-analysis
Wing Ying Au, Peter Pak‐Hang Cheung
BMJ (2022), pp. e069989-e069989
Open Access | Times Cited: 126
Effectiveness of COVID-19 vaccines against Omicron or Delta symptomatic infection and severe outcomes
Sarah A. Buchan, Hannah Chung, Kevin A. Brown, et al.
medRxiv (Cold Spring Harbor Laboratory) (2022)
Open Access | Times Cited: 120
Association of Primary and Booster Vaccination and Prior Infection With SARS-CoV-2 Infection and Severe COVID-19 Outcomes
D. Y. Lin, Yu Gu, Yangjianchen Xu, et al.
JAMA (2022) Vol. 328, Iss. 14, pp. 1415-1415
Open Access | Times Cited: 113
SARS‐CoV‐2 Omicron variant: Immune escape and vaccine development
Danyi Ao, Tianxia Lan, Xuemei He, et al.
MedComm (2022) Vol. 3, Iss. 1
Open Access | Times Cited: 105
mRNA vaccines in disease prevention and treatment
Gang Zhang, Tianyu Tang, Yinfeng Chen, et al.
Signal Transduction and Targeted Therapy (2023) Vol. 8, Iss. 1
Open Access | Times Cited: 96
Page 1 - Next Page

Scroll to top